2022
CABOSEQ: The Effectiveness of Cabozantinib in Patients With Treatment Refractory Advanced Renal Cell Carcinoma: Results From the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC)
Navani V, Wells J, Boyne D, Cheung W, Brenner D, McGregor B, Labaki C, Schmidt A, McKay R, Meza L, Pal S, Donskov F, Beuselinck B, Otiato M, Ludwig L, Powles T, Szabados B, Choueiri T, Heng D. CABOSEQ: The Effectiveness of Cabozantinib in Patients With Treatment Refractory Advanced Renal Cell Carcinoma: Results From the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC). Clinical Genitourinary Cancer 2022, 21: 106.e1-106.e8. PMID: 35945133, DOI: 10.1016/j.clgc.2022.07.008.Peer-Reviewed Original ResearchMeSH KeywordsAngiogenesis InhibitorsCarcinoma, Renal CellHumansKidney NeoplasmsRetrospective StudiesSunitinibVascular Endothelial Growth Factor AConceptsInternational Metastatic Renal Cell Carcinoma Database ConsortiumIpilimumab-nivolumabOverall survivalTreatment failureAdvanced renal cell carcinomaActivity of cabozantinibClinically meaningful activityMedian TTFEffects of cabozantinibGrowth factor inhibitorsRenal cell carcinomaMultivariate Cox regressionMedian OSRetrospective observational naturePoor riskCell carcinomaFactor inhibitorsCabozantinibCox regressionResponse ratePatientsOverall populationObservational natureVEGFiMonthsOutcomes of patients with advanced non-clear cell renal cell carcinoma treated with first-line immune checkpoint inhibitor therapy
Graham J, Wells J, Dudani S, Gan C, Donskov F, Lee J, Kollmannsberger C, Meza L, Beuselinck B, Hansen A, North S, Bjarnason G, Sayegh N, Kanesvaran R, Wood L, Hotte S, McKay R, Choueiri T, Heng D. Outcomes of patients with advanced non-clear cell renal cell carcinoma treated with first-line immune checkpoint inhibitor therapy. European Journal Of Cancer 2022, 171: 124-132. PMID: 35717820, DOI: 10.1016/j.ejca.2022.05.002.Peer-Reviewed Original ResearchConceptsInternational Metastatic RCC Database ConsortiumImmune checkpoint inhibitor groupImmune checkpoint inhibitorsVascular endothelial growth factorICI-based therapyObjective response rateVascular endothelial growth factor groupMammalian target of rapamycinClear-cell renal cell carcinomaFirst-line therapyOutcomes of patientsRenal cell carcinomaTreatment failureOverall survivalInhibitor monotherapyCell carcinomaFirst-lineAdvanced non-clear cell renal cell carcinomaInternational Metastatic RCC Database Consortium risk groupMammalian target of rapamycin-targeted therapiesMetastatic clear-cell renal cell carcinomaNon-clear cell renal cell carcinomaNon-clear cell RCCAssociated with improved OSMedian TTF
2021
Circulating cytokines associated with clinical response to systemic therapy in metastatic renal cell carcinoma
Chehrazi-Raffle A, Meza L, Alcantara M, Dizman N, Bergerot P, Salgia N, Hsu J, Ruel N, Salgia S, Malhotra J, Karczewska E, Kortylewski M, Pal S. Circulating cytokines associated with clinical response to systemic therapy in metastatic renal cell carcinoma. Journal For ImmunoTherapy Of Cancer 2021, 9: e002009. PMID: 33688021, PMCID: PMC7944971, DOI: 10.1136/jitc-2020-002009.Peer-Reviewed Original ResearchConceptsVascular endothelial growth factor tyrosine kinase inhibitorMetastatic renal cell carcinomaRenal cell carcinomaImmune checkpoint inhibitorsColony-stimulating factorClinical benefitPlasma cytokinesSystemic therapyCell carcinomaInterleukin-6Prospective correlative studyLines of therapyLow pretreatment levelsGranulocyte colony-stimulating factorGranulocyte-macrophage colony-stimulating factorRCC histologic subtypesMacrophage colony-stimulating factorICI armsICI therapyStable diseaseCheckpoint inhibitorsClinical responsePartial responseComplete responseImmunologic profile